The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of Respiratory Syncytial Virus (RSV) infections and related disorders, including bronchiolitis and viral pneumonia. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against RSV. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against RSV infection, confer immunity against RSV infection, protect against RSV infection, and reduce the likelihood of infection by RSV infection.